Indeed, MYBL2 is one of a small number of genes included in the Oncotype DX gene expression test that is widely used to predict clinical outcomes and plan treatment for patients with breast cancer (Bhutiani et al., 2019; Paik et al., 2004). Here, MYBL2 is linked to breast carcinoma.